Since then blinatumomab, a CD3/CD19 bispecific T-cell engager has been licensed for the treatment of Philadelphia-chromosome negative and Philadelphia-chromosome positive R/R B-precursor ALL [13]. Here, CD19 is linked to acute lymphoblastic leukemia.